Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

Diagnosis of malignant disease

No prior chemotherapy and scheduled to receive HEC (either cisplatin-containing regimen or anthracycline + cyclophosphamide [AC])

Cisplatin at a dose of ≥70mg/m^2, with or without other chemotherapy agent(s) OR

Anthracycline (60 mg/m^2) plus cyclophosphamide(600 mg/m^2)

Age ≥18 years

Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2

Required Initial Laboratory Values ≤ 120 days prior to registration

Serum Creatinine ≤2.0 mg/dL

Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic oxaloacetic transaminase (SGPT) ≤3 x Upper Limit of Normal (ULN)

Absolute neutrophil count (ANC) ≥1500/mm^3

No nausea or vomiting ≤ 24 hours prior to registration

Negative pregnancy test (serum or urine) done ≤7 days prior to registration, for women of childbearing potential only (per clinician discretion)

No severe cognitive compromise

No known history of CNS disease (e.g. brain metastases, seizure disorder)

No treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone ≤30 days prior to registration or planned during protocol therapy

No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue anti-emetic therapy)

No concurrent use of amifostine

No concurrent abdominal radiotherapy

No concurrent use of quinolone antibiotic therapy

No chronic alcoholism (as determined by the investigator)

No known hypersensitivity to olanzapine

No known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months.

No history of uncontrolled diabetes mellitus (e.g. on insulin or an oral hypoglycemic agent)